Skip to content


Trogarzo (ibalizumab) is an antibody pharmaceutical. Ibalizumab was first approved as Trogarzo on 2018-03-06. It is used to treat HIV infections in the USA. It has been approved in Europe to treat HIV infections. The pharmaceutical is active against T-cell surface glycoprotein CD4.
Trade Name Trogarzo
Common Name Ibalizumab
Indication hiv infections
Drug Class Monoclonal antibodies: humanized, immunomodulating
Get full access now